Cempra, Inc., a clinical-stage biopharmaceutical company, engages in developing antibiotics for the treatment of bacterial infectious diseases. It focuses on developing antibiotics for treating respiratory tract, and skin and skin structure infections. The company's antibiotic candidates in clinical trials stage include Solithromycin, an oral and intravenous fluoroketolide for the treatment of community-acquired bacterial pneumonia; and TAKSTA, a fusidic acid that is active against gram-positive pathogens, including hospital and community-acquired methicillin-resistant S. aureus. Its preclinical programs focus on the discovery, development, and commercialization of macrolides; non-antibacterial preclinical candidates; and research on non-antibacterial candidates. The company was formerly known as Cempra Holdings, LLC and changed its name to Cempra, Inc. in February 2012. Cempra, Inc. was founded in 2005 and is headquartered in Chapel Hill, North Carolina.